🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

953 results for “injection” Clear

  1. Placebo - Sodium Chloride 9 mg/ml (0.9%) - Solution for injection, ARO-DM1

    Sarepta Therapeutics

    Type 1 Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  2. Placebo A, NNC0519-0130, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    Chronic Kidney Disease, with or without Type 2 diabetes, Obesity

    phase 2 small molecule active

    1 trial

  3. Placebo A, Semaglutide B Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    type 2 diabetes

    phase 2 small molecule active

    1 trial

  4. Placebo comparator, intramuscular injection, TRI-001

    Ferring Pharmaceuticals

    Patients with Chronic Limb Threatening Ischemia (CLTI) due to Peripheral Arterial Disease (PAD)

    phase 2 small molecule active

    1 trial

  5. Placebo for AZD2693 Solution for Injection, Placebo for AZD2693 Solution for Injection

    AstraZeneca AB

    Non-cirrhotic non-alcoholic steatohepatitis with fibrosis

    phase 2 small molecule active

    1 trial

  6. Placebo for Bepirovirsen Solution for Injection, 150 mg/mL SSD

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial

  7. Placebo for ponsegromab (PF-06946860) solution for injection, Ponsegromab (PF-06946860)

    Pfizer Australia Pty Ltd

    Cancer cachexia

    phase 2 small molecule active

    1 trial

  8. Placebo solution for injection matching COR-1167, COR-1167

    Lacuna Pharma Pty Ltd

    Worsening Heart Failure

    phase 2 small molecule active

    1 trial

  9. Placebo sterile solution for SC injection, Obexelimab

    Zenas BioPharma

    RELAPSING MULTIPLE SCLEROSIS

    phase 2 small molecule active

    1 trial

  10. Placebo to MAS825 100 mg/1 mL Concentrate for solution for infusion / Solution for injection, -, CICLOSPORIN , MAS825

    Novartis Pharmaceuticals

    Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.

    phase 2 small molecule active

    1 trial

  11. Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230

    Novartis Pharmaceuticals

    Calcific Aortic Valve Stenosis

    phase 2 small molecule active

    1 trial

  12. Placebo to match DNTH103, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, DNTH103, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, c

    Dianthus Therapeutics, Inc. /DE/

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  13. Placebo: Normal Saline - Solution for injection, Daxdilimab

    Elan Pharma International

    Primary Discoid Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  14. Pluvicto 1 000 MBq/mL solution for injection/infusion

    Ningbo Cancer Hospital

    Clear Cell Renal Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  15. Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation

    Novartis Pharmaceuticals

    Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.

    phase 2 small molecule active

    1 trial

  16. Polivy 30 mg powder for concentrate for solution for infusion., Epcoritamab (GEN3013), Truxima 100 mg concentrate for solution for infusion, IMBRUVICA 140 mg hard capsules, Golcadomide, Revlimid 10 mg hard capsules, IMBRUVICA 140 mg hard capsules, PIRTOBRUTINIB, Cyclophosphamide Injection 500 mg., Venetoclax, Venetoclax, Epcoritamab (GEN3013), Revlimid 25 mg hard capsules, Venetoclax, Decortin® H 20 mg Tabletten, Truxima 500 mg concentrate for solution for infusion, Decortin® H 5 mg Tabletten, Adriblastin®

    AbbVie Deutschland GmbH & Co. KG

    B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  17. Ponsegromab (PF-06946860), Placebo for ponsegromab (pf-06946860) solution for injection

    Pfizer Australia Pty Ltd

    Heart failure

    phase 2 small molecule active

    1 trial

  18. Posaconazol STADA 100 mg magensaftresistente Tabletten, S65487 Solution for infusion 100 mg, Vidaza 25 mg/ml powder for suspension for injection

    The George Institute

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  19. Privigen 100 mg/ml solution for infusion, Saline, 0.9% Sodium Chloride Solution for Injection, JNJ-80202135, JNJ-80202135

    Janssen-Cilag International N.V.

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 2 small molecule active

    1 trial

  20. Puregon 300 IU/0.36 mL solution for injection, Cetrotide 0.25 mg powder and solvent for solution for injection, NOLVADEX 10 mg, comprimé pelliculé, Ovitrelle 250 micrograms solution for injection in pre-filled pen

    CERO THERAPEUTICS HOLDINGS, INC.

    Breast cancer

    phase 2 small molecule active

    1 trial

  21. RBD3000 Placebo Injection is a clear, colorless sterile solution for subcutaneous injection, which is formulated by 25 mM phosphate buffer

    Lacuna Pharma Pty Ltd

    Mixed Dyslipidemia

    phase 2 small molecule active

    1 trial

  22. RBD4059 injection, Trombyl 75 mg tabletter, The corresponding placebo consist of the 25 mM phosphate buffer solution with 2 µg of vitamin b2 added for colouring purposes only

    Lacuna Pharma Pty Ltd

    Stable Coronary Artery Disease

    phase 2 small molecule active

    1 trial

  23. REKOVELLE 72 micrograms/2.16 mL solution for injection in a pre-filled pen, Pre-filled pen containing 2.16mL solution, subcutaneous injection

    Ferring Pharmaceuticals

    Idiopathic male infertility (including oligoasthenozoospermia).

    phase 2 small molecule active

    1 trial

  24. RO7204239, RO7204239 Placebo, Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-f

    Hoffmann-La Roche

    Obesity

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources